HDP-101, a novel antibody-drug conjugate, targets BCMA with a synthetic amanitin payload that causes tumor cell death.

Another breakthrough has been with ADCs in combination with other treatments, such as an immunotherapy that inhibits the ...

Lifordi Immunotherapeutics, Inc., today announced that it has received the Endpoints 11 Award from Endpoints News, an honor ...

Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector.

It represents 82% of the ADC pipeline in major APAC markets. A surge in antibody-drug conjugates (ADCs) is driving China to ...

编者按： 2024年欧洲肿瘤内科学会（ESMO）年会于当地时间9月13日~17日在西班牙巴塞罗那召开。作为肿瘤学界的年度盛典，ESMO每年都会吸引上万名世界各地的肿瘤学大咖，为全球学者提供了良好的交流平台。今年， 复旦大学附属肿瘤医院叶定伟教授团队 ...

为何EGFR/HER3双抗在尿路上皮癌中表现出出色的疗效信号，对于其分子机制的探索还有很长的路要走。从目前已知的机制来说：EGFR和HER3在膀胱癌中具有很高的表达率，且EGFR与HER3的激活或突变与肿瘤发展、耐药等密切相关。

First Drug Is Expected To Be Available In Market By 2029 Says Kuick In Its ReportDelhi, Sept. 17, 2024 (GLOBE NEWSWIRE) -- ...

Treatment with the antibody-drug conjugate TORL-1-23 was safe and tolerable in heavily pretreated, CLDN6-positive advanced solid tumors, including platinum-resistant ovarian cancer.

AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...

Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat ...

The drug helped patients live significantly longer without their cancer progressing, compared with patients who were treated ...